Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...

As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 34% of the $80 billion-plus diabetes treatment market and roughly half of the more than $15 billion ...

Novo Nordisk reported strong data for its next ... Amycretin is a GLP-1 agonist, but it also mimics the action of another hormone, amylin, that regulates blood sugar and satiety.

Novo Nordisk forecast slower sales growth for 2025 of between 16% to 24 ... work by mimicking a hormone called glucagon-like peptide-1, which suppresses appetite. Investors have now been eagerly ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.

and hormone therapies. 2024 was a strong year for Novo Nordisk A/S (NYSE:NVO), with sales climbing 25% to $40.6 billion, but the company expects growth to slow in 2025. The stock has dropped 40% ...